SAB Biotherapeutics (SABS) Other Non-Current Liabilities: 2021-2024

Historic Other Non-Current Liabilities for SAB Biotherapeutics (SABS) over the last 4 years, with Dec 2024 value amounting to $6.4 million.

  • SAB Biotherapeutics' Other Non-Current Liabilities fell 41.67% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 41.67%. This contributed to the annual value of $6.4 million for FY2024, which is 45.74% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Other Non-Current Liabilities of $6.4 million as of FY2024, which was down 45.74% from $11.8 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Other Non-Current Liabilities registered a high of $11.8 million during FY2023, and its lowest value of $320,930 during FY2022.
  • In the last 3 years, SAB Biotherapeutics' Other Non-Current Liabilities had a median value of $6.4 million in 2024 and averaged $6.2 million.
  • Per our database at Business Quant, SAB Biotherapeutics' Other Non-Current Liabilities tumbled by 97.01% in 2022 and then surged by 3,568.79% in 2023.
  • Over the past 4 years, SAB Biotherapeutics' Other Non-Current Liabilities (Yearly) stood at $10.7 million in 2021, then crashed by 97.01% to $320,930 in 2022, then skyrocketed by 3,568.79% to $11.8 million in 2023, then tumbled by 45.74% to $6.4 million in 2024.